Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (IGC) is at the forefront of developing innovative phytocannabinoid-based therapies aimed at treating a wide range of therapeutic indications. The company is involved in cutting-edge research to develop treatments for conditions such as neuropathic and cancer pain, epilepsy, and chronic neurological and oncological diagnoses, which can be life-altering or life-threatening. The mission of IGC Pharma is to alleviate pain, PTSD, seizures, cachexia, and other severe conditions through advanced cannabinoid-based formulations.
One of the primary focuses of IGC Pharma is to combat Alzheimer's disease. The company has developed two investigational drug assets, IGC-AD1 and TGR-63, that have shown potential in reducing key hallmarks of Alzheimer's, such as plaques and tangles, in cell line studies. IGC-AD1, a low-dose tetrahydrocannabinol-based formulation, is currently undergoing a Phase 2 clinical trial involving 146 participants to evaluate its efficacy in treating agitation in dementia due to Alzheimer's.
Beyond Alzheimer's treatment, IGC Pharma also addresses women's health through its wellness brand Holief, which provides relief for premenstrual syndrome and menstrual cramps. This diversified approach highlights the company’s commitment to improving quality of life across various patient demographics.
IGC Pharma's innovative research and development are complemented by strategic partnerships and a robust product portfolio, which collectively enhance its market presence and potential for growth.
Rhea-AI Summary
IGC Pharma, Inc. announced positive results of preclinical studies for TGR-63, a potential treatment for Alzheimer's disease. The company aims to target a Phase 1 trial in 2024. TGR-63 showed positive impacts on plaque burden and anxiety reduction in transgenic Alzheimer's mouse models. The use of AI/ML tools is planned to accelerate the journey of TGR-63 from preclinical to patient care. CEO Ram Mukunda expressed enthusiasm and anticipation for clinical milestone updates throughout 2024 from the company's strengthened AD pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IGC Pharma, Inc. provides details on its potential Alzheimer’s drug candidate TGR-63, which has shown promising results in disrupting the formation of amyloid-beta plaque in the brain. The drug has exhibited potency in alleviating plaque burden in Alzheimer’s cell lines and genetically modified mouse models. Additionally, TGR-63 has demonstrated excellent biocompatibility and the ability to penetrate the blood-brain barrier. The company is also advancing IGC-AD1, a CB1 receptor partial agonist, through a Phase 2b trial aimed at alleviating agitation in dementia due to Alzheimer’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IGC Pharma, Inc. (NYSE American: IGC) announced that ClinCloud has dosed its first patient in a Phase 2b trial investigating the safety and efficacy of IGC-AD1 on agitation in Alzheimer’s Disease. The trial aims to develop an innovative therapy for addressing the significant distress caused by agitation in Alzheimer's patients. The expansion of the trial network underscores the commitment to a robust, scientifically driven approach, with 12 sites in the US and Canada. The trial will enroll 146 patients, with one half receiving IGC-AD1 and the other half receiving a placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
News
Rhea-AI Summary
IGC Pharma, Inc. (NYSE American: IGC) announced the issuance of a patent for its treatment of Alzheimer’s disease, IGC-AD1, by the Divisional Direction of Patents, Mexico. The company is optimistic about potential approvals in the U.S. and Europe, and the success in Mexico is seen as a positive step towards commercialization. IGC-AD1 is a partial CB1 receptor agonist designed to address neurodegeneration in Alzheimer’s patients, with a Phase 2 trial currently underway. The company is also pursuing patent protection for IGC-AD1 in multiple jurisdictions. Alzheimer’s disease is a growing public health issue, and IGC-AD1 aims to improve the quality of life for affected individuals. IGC Pharma is also developing four other drug assets targeting agitation related to Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
-
Rhea-AI Summary
IGC Pharma, Inc. (NYSE American: IGC) to Participate in Biotech Showcase and BIO Partnering @ JPM alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IGC Pharma, Inc. (IGC) announced a partnership with Los Andes University’s Center for Research and Training in Artificial Intelligence to leverage Generative AI for disease signature analysis. The collaboration aims to accelerate treatment delivery to patients, particularly those with Alzheimer's disease. IGC Pharma is developing assets targeting Alzheimer's disease, including IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, in different stages of development. The company's CEO, Ram Mukunda, highlighted the potential of AI integration to reduce risk in clinical trials and expedite treatment for Alzheimer's patients. The collaboration with CINFONIA is expected to reveal hidden relationships in clinical trial data and improve treatment efficacy for IGC-AD1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
IGC Pharma, Inc. (IGC) (NYSE American: IGC) announced a Master Cooperation Agreement with the University of Los Andes for the development and adoption of generative AI solutions into the Company’s drug identification, development, and clinical trial processes. The agreement focuses on advancing AI initiatives to streamline clinical trial efficiency, enhance early detection methods for Alzheimer’s disease, and improve drug interaction analysis. IGC Pharma is currently pursuing five drug assets targeting the treatment of agitation related to symptoms of Alzheimer's disease, with IGC-AD1 in Phase 2 clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
Rhea-AI Summary
IGC Pharma, Inc. (NYSE American: IGC) reports 44% revenue growth in Q2 FY2024, signaling progress in Phase 2 Trial for Alzheimer’s treatment. The company is focused on expanding its IP portfolio targeting Alzheimer’s, addressing agitation in dementia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
News
Rhea-AI Summary
IGC Pharma, Inc. has been granted a European patent for its innovative cannabinoid composition and method for treating pain. The company aims to revolutionize pain relief by offering a cream or gel infused with cannabinoids that provides effective pain relief without psychotropic or adverse side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
IGC Pharma, Inc. announces approval of proposals at Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of IGC Pharma (IGC)?
The current stock price of IGC Pharma (IGC) is $0.379 as of December 20, 2024.
What is the market cap of IGC Pharma (IGC)?
The market cap of IGC Pharma (IGC) is approximately 27.3M.
What is the main focus of IGC Pharma, Inc.?
IGC Pharma focuses on developing phytocannabinoid-based therapies for various severe conditions, including neuropathic pain, Alzheimer's disease, and chronic neurological diagnoses.
What are IGC Pharma's key investigational drug assets for Alzheimer's?
IGC Pharma's key investigational drugs for Alzheimer's are IGC-AD1 and TGR-63, which have shown promise in reducing Alzheimer's biomarkers in cell line studies.
What is the status of IGC-AD1?
IGC-AD1 is in a Phase 2 clinical trial with 146 participants, aimed at evaluating its efficacy in treating agitation in dementia due to Alzheimer's.
Does IGC Pharma have products targeting women's health?
Yes, IGC Pharma markets the Holief brand, which targets women experiencing premenstrual syndrome and menstrual cramps.
What conditions does IGC Pharma aim to treat with its therapies?
IGC Pharma aims to treat conditions such as pain, PTSD, seizures, cachexia, Alzheimer's disease, and other chronic and terminal neurological and oncological diagnoses.
How does IGC Pharma contribute to Alzheimer's research?
IGC Pharma contributes through its development of IGC-AD1 and TGR-63, which target key hallmarks of Alzheimer's disease, such as plaques and tangles.
What is the mission of IGC Pharma?
The mission of IGC Pharma is to treat severe and life-altering conditions using advanced cannabinoid-based formulations.
What is the significance of IGC's research on neuropathic and cancer pain?
IGC's research aims to provide effective phytocannabinoid-based therapies for managing neuropathic and cancer pain, improving patient quality of life.
Does IGC Pharma have any products in the wellness market?
Yes, IGC Pharma's wellness brand Holief targets women suffering from premenstrual syndrome and menstrual cramps.
What makes IGC Pharma unique in the biotech industry?
IGC Pharma's unique approach lies in its focus on phytocannabinoid-based therapies, targeting a wide range of severe conditions, and its diverse product portfolio including wellness products.
IGC Pharma, Inc.
NYSE:IGC
IGC Rankings
IGC Stock Data
27.33M
71.46M
7.92%
22%
1.62%
Biotechnology
Pharmaceutical Preparations
United States of America
POTOMAC